Filter Results:
(446)
Show Results For
- All HBS Web
(631)
- People (2)
- News (54)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
Show Results For
- All HBS Web
(631)
- People (2)
- News (54)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
Sort by
- October 2002
- Case
A Father's Love: Novazyme Pharmaceuticals, Inc.
By: Richard M.J. Bohmer and Bradley Campbell
John Crowley, CEO of Novazyme Pharmaceuticals, a start-up biotechnology firm developing an orphan drug to treat a rare lysosomal storage disorder from which his children suffer, must choose between a partnership and a buyout to have sufficient funds and support to get... View Details
Keywords: Technological Innovation; Business Startups; Partners and Partnerships; Financing and Loans; Governing Rules, Regulations, and Reforms; Sales; Price; Product Development; Motivation and Incentives; Decision Choices and Conditions; Biotechnology Industry; Biotechnology Industry
Bohmer, Richard M.J., and Bradley Campbell. "A Father's Love: Novazyme Pharmaceuticals, Inc." Harvard Business School Case 603-048, October 2002.
- 13 Jan 2003
- Research & Ideas
Making Biotech Work as a Business
for example, was a banner year for bad news, with thirty late-stage clinical failures of biotech drugs, he said. The online magazine Signals, which is published by Recombinant Capital, a consulting firm that works on biotechnology... View Details
- March 2022
- Case
Tensions at SearchLight Cures
By: Laura Huang and Sarah Mehta
This general experience case tells the story of SearchLight Cures, a fictional biotechnology startup. Having discovered a new therapy for a rare disease, the company’s co-founders find themselves at an impasse over a pricing disagreement. View Details
Keywords: Business Ventures; Business Growth and Maturation; Business Startups; Communication; Interpersonal Communication; Values and Beliefs; Management; Negotiation; Relationships; Partners and Partnerships; Science; Biotechnology Industry; United States; California; San Francisco
Huang, Laura, and Sarah Mehta. "Tensions at SearchLight Cures." Harvard Business School Case 422-059, March 2022.
- February 2010 (Revised September 2011)
- Case
Roche's Acquisition of Genentech
By: Carliss Y. Baldwin, Bo Becker and Vincent Marie Dessain
Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and... View Details
Keywords: Mergers and Acquisitions; Business Subsidiaries; Negotiation Offer; Organizational Culture; Corporate Strategy; Biotechnology Industry; Biotechnology Industry; Switzerland
Baldwin, Carliss Y., Bo Becker, and Vincent Marie Dessain. "Roche's Acquisition of Genentech." Harvard Business School Case 210-040, February 2010. (Revised September 2011.)
- October 2001 (Revised May 2002)
- Case
Proteome Systems Limited
A Sydney-based biotechnology company is attempting to enter the fast-growing proteomics area. This case highlights choices in business design and changes in these over time. Also addresses issues in geographic location. View Details
Keywords: Organizational Change and Adaptation; Geographic Location; Market Entry and Exit; Biotechnology Industry; Sydney
West, Jonathan, and Mona Ashiya. "Proteome Systems Limited." Harvard Business School Case 602-039, October 2001. (Revised May 2002.)
- September 2019
- Case
Nimbus Therapeutics
By: Peter Barrett, Karim Lakhani and Julia Kelley
This case focuses on Nimbus Therapeutics, a biotechnology startup based in Cambridge, Massachusetts, as its leadership team tries to determine the company’s long-term strategy. The startup’s founders structured Nimbus as a limited liability company, which has given it... View Details
Barrett, Peter, Karim Lakhani, and Julia Kelley. "Nimbus Therapeutics." Harvard Business School Case 620-016, September 2019.
- November 2008
- Case
Adnexus Therapeutics, Inc.: Considering the Exit
By: Vicki L. Sato and Rachel Gordon
Dr. John Mendlein, CEO of Adnexus Therapeutics Inc. (Adnexus), a private biotechnology company, must decide whether to pursue acquisition talks with Bristol-Myers Squibb (BMS) after a successful six-month collaboration or continue with Adnexus' planned IPO. View Details
Keywords: Mergers and Acquisitions; Decision Choices and Conditions; Entrepreneurship; Initial Public Offering; Corporate Strategy; Biotechnology Industry
Sato, Vicki L., and Rachel Gordon. "Adnexus Therapeutics, Inc.: Considering the Exit." Harvard Business School Case 609-015, November 2008.
- June 1997 (Revised October 2001)
- Case
Elliot Lebowitz
By: Paul A. Gompers and Alexander Tsai
Elliot Lebowitz, president and CEO of BioTransplant, must decide on a strategy for this young biotechnology start-up. Among the issues to be resolved are focus of research and search for strategic alliance partners. View Details
Keywords: Alliances; Research; Business Startups; Management Teams; Business Strategy; Biotechnology Industry; United States
Gompers, Paul A., and Alexander Tsai. "Elliot Lebowitz." Harvard Business School Case 297-094, June 1997. (Revised October 2001.)
- Research Summary
Interfirm Alliances as Competitive Weapons
How do alliances affect the evolution of an industry and its constituent firms? Silverman is examining the dynamics of alliance- and patent-based competition in the Canadian biotechnology industry. Recent empirical research focuses on the effect of alliance patterns... View Details
- December 1992 (Revised September 1996)
- Case
ImmuLogic Pharmaceutical Corporation (Abridged)
By: Josh Lerner
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The rationales for and problems of high-technology start-ups are explored. The challenges posed by "windows" for public offerings are... View Details
Keywords: Decisions; Initial Public Offering; Entrepreneurship; Going Public; Business Startups; Biotechnology Industry; Biotechnology Industry; United States
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (Abridged)." Harvard Business School Case 293-087, December 1992. (Revised September 1996.)
- June 1997 (Revised March 2001)
- Case
Genset Initial Public Offering (A)
By: Paul A. Gompers and Jeffrey M. Anapolsky
Pascal Brandys, founder and CEO of Genset, must decide whether to take this young biotechnology company public. If so, should he do a dual offering in both France and the U.S.? The case also explores the business models in genomics research. View Details
Keywords: Business Model; Initial Public Offering; Genetics; Going Public; Management Teams; Biotechnology Industry; France; United States
Gompers, Paul A., and Jeffrey M. Anapolsky. "Genset Initial Public Offering (A)." Harvard Business School Case 297-096, June 1997. (Revised March 2001.)
- 2018
- Chapter
Are Licensing Markets Local? An Analysis of the Geography of Vertical Licensing Agreements in Bio-Pharmaceuticals
By: Juan Alcacer, John Cantwell and Michelle Gittelman
As the value chain of the pharmaceutical industry disaggregates, upstream discovery is increasingly carried out by small research-specialized firms while downstream development, testing and marketing is conducted by global pharmaceutical firms. Licensing plays an... View Details
Keywords: Geographic Location; Local Range; Rights; Research and Development; Biotechnology Industry; Biotechnology Industry
Alcacer, Juan, John Cantwell, and Michelle Gittelman. "Are Licensing Markets Local? An Analysis of the Geography of Vertical Licensing Agreements in Bio-Pharmaceuticals." In Location of Biopharmaceutical Activity, edited by Iain M. Cockburn and Matthew J. Slaughter. National Bureau of Economic Research, forthcoming.
- January 2007
- Background Note
Note on Biotech Business Development
By: Richard G. Hamermesh and Robert F. Higgins
Describes the business development process in biotechnology companies. Topics covered include: participants in the licensing process and their interests, the major steps in the licensing process, the terms that are part of most agreements, and the most contentious... View Details
Keywords: Agreements and Arrangements; Entrepreneurship; Intellectual Property; Biotechnology Industry
Hamermesh, Richard G., and Robert F. Higgins. "Note on Biotech Business Development." Harvard Business School Background Note 807-032, January 2007.
- October 1992 (Revised November 1997)
- Case
ImmuLogic Pharmaceutical Corporation (A): March 1991
By: Josh Lerner
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The diverse perspectives of the entrepreneur, venture capitalist, investment banker, and institutional investor are explored. Problems... View Details
Keywords: Decisions; Entrepreneurship; Venture Capital; Banks and Banking; Initial Public Offering; Going Public; Perspective; Valuation; Biotechnology Industry; Biotechnology Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (A): March 1991." Harvard Business School Case 293-066, October 1992. (Revised November 1997.)
- August 2001
- Case
Scios, Inc.
Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details
- March 1997
- Case
BioTransplant, Inc.: Initial Public Offering, January 1996
By: Paul A. Gompers and Alexander Tsai
Examines the decision to go public. BioTransplant is an early stage biotechnology company that must decide how to finance its research and development. The pros and cons of public offerings are analyzed versus alternative financing sources. View Details
Gompers, Paul A., and Alexander Tsai. "BioTransplant, Inc.: Initial Public Offering, January 1996." Harvard Business School Case 297-095, March 1997.
- November 1991 (Revised April 1994)
- Case
Nucleon, Inc.
By: Gary P. Pisano
Nucleon is a small biotechnology company whose first potential product is about to enter clinical testing. Before Nucleon can begin clinical trials, however, its management must decide how and where to manufacture the product. Three options are being contemplated: 1)... View Details
Keywords: Factories, Labs, and Plants; Entrepreneurship; Health Testing and Trials; Rights; Product Development; Production; Partners and Partnerships; Research and Development; Biotechnology Industry
Pisano, Gary P. "Nucleon, Inc." Harvard Business School Case 692-041, November 1991. (Revised April 1994.)
- June 2011 (Revised October 2013)
- Case
Gene Patents (A)
By: Richard Hamermesh, David Kiron and Phillip Andrews
In March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues... View Details
Keywords: Courts and Trials; Patents; Genetics; Judgments; Science-Based Business; Biotechnology Industry; United States
Hamermesh, Richard, David Kiron, and Phillip Andrews. "Gene Patents (A)." Harvard Business School Case 811-089, June 2011. (Revised October 2013.)
- September 1999 (Revised September 2005)
- Case
Strategic Deal Making at Millennium Pharmaceuticals
A small start-up in 1993, Millennium Pharmaceuticals was a name-brand biotechnology company by the end of 1998, with a market capitalization of $1.4 billion. The Cambridge-based company's growth strategy had relied heavily on building alliances for early-stage drug... View Details
Keywords: Alliances; Negotiation Deal; Growth and Development Strategy; Pharmaceutical Industry; Cambridge
Watkins, Michael D., and Sarah Matthews. "Strategic Deal Making at Millennium Pharmaceuticals." Harvard Business School Case 800-032, September 1999. (Revised September 2005.)
- Research Summary
Research Interests
Research interests are focused on issues of innovation and productivity as they relate to improved outcomes in biotechnology and pharmaceutical R and D. These span topics from decision-making, organizational structure and communication, to the development of novel... View Details